Abstract: Antibodies with fully human variable regions against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled. Various subsequent manipulations can be performed to obtain either antibodies per se or analogs thereof.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
June 13, 2000
Assignee:
Abgenix, Inc.
Inventors:
Raju Kucherlapati, Aya Jakobovits, Sue Klapholz, Daniel G. Brenner, Daniel J. Capon
Abstract: A method is disclosed of reducing viral replication of a virus of the paramyxoviridae family in a host, comprising administering to the host an antigen of the virus in combination with an effective adjuvant amount of interleukin-12 (IL-12). Human viruses of the paramyxoviridae family include paramyxoviruses (e.g., parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3 and parainfluenza virus 4), morbilliviruses (e.g., measles virus) and pneumoviruses (e.g., respiratory syncytial virus); other non-human viruses of the paramyxoviridae family include canine distemper virus, bovine respiratory syncytial virus, Newcastle disease virus and rhinderpest virus. A composition is also disclosed comprising a mixture of an antigen of a virus of the Paramyxoviridae family and an effective adjuvant amount of interleukin-12 (IL-12).
Abstract: A method for screening substances for oncogenic activity is disclosed. The method involves administering the substance to an animal lacking responsiveness to interferon.gamma. and detecting a higher frequency or earlier time of tumor formation in the test animal compared to control animals. In addition, a method is provided for predicting the aggressiveness of a tumor in a patient.
Abstract: The p21 gene encodes a cyclin dependent kinase inhibitor which affects cell cycle progression, but the role of this gene product in altering tumor growth has not been established. The present inventors have now discovered that the growth of malignant cells in vivo is inhibited by expression of p21. Expression of p21 resulted in an accumulation of cells in G.sub.0 /G.sub.1, alteration in morphology, and cell differentiation.
Type:
Grant
Filed:
February 26, 1998
Date of Patent:
May 2, 2000
Assignee:
University of Michigan
Inventors:
Gary J. Nabel, Zhi-yong Yang, Elizabeth G. Nabel
Abstract: A keratin K1 vector for expression of a nucleic acid sequence in an epidermal cell. The vector includes a 5' flanking region which includes necessary sequences for expression of a nucleic acid cassette, a keratin K1 3' flanking region which regulates expression of a nucleic acid sequence, predominantly in the epidermis, and a linker which connects the 5' flanking region to a nucleic acid. The linker has a position for inserting a nucleic acid cassette. The linker does not contain the coding sequence of a gene that the linker is naturally associated with. That is, the linker is not the normal gene associated with the 5' and 3' regions.
Type:
Grant
Filed:
May 30, 1995
Date of Patent:
May 2, 2000
Assignees:
Baylor College of Medicine, The United States of America as represented by the Department of Health and Human Services
Inventors:
Dennis R. Roop, Joseph A. Rothnagel, David A. Greenhalgh, Stuart H. Yuspa
Abstract: This invention is directed to a chimeric mouse capable of mounting murine cellular and humoral immune response, where the chimeric mouse is tolerant of human tissue implanted therein. The chimeric mouse of this invention is capable of developing murine T cells and producing murine IgG antibodies, which T cells and antibodies are tolerant of the human tissue implanted in the mouse. This allows for the challenge of the vaccinated mouse with human-specific pathogens and determining the capacity of the vaccine to protect the cells in the implanted tissue from infection. This invention is also directed to a method for the development of the chimeric mouse, as well as to the use of the chimeric mouse for the screening of vaccines for human-specific pathogens.
Type:
Grant
Filed:
July 15, 1998
Date of Patent:
April 25, 2000
Assignee:
Albert Einstein College of Medicine of Yeshiva University
Abstract: The invention provides a method of radiosensitizing a tumor in a subject by contacting the tumor with a cytokine or a nucleic acid molecule encoding a cytokine. The invention also provides a method of radiosensitizing a tumor in a subject by administering, at a site other than the tumor, a cell genetically modified to express a cytokine. The invention further provides a method of reducing the severity of a cancer in a subject by administering a cytokine at the site of the tumor or by immunizing the subject at a site other than the tumor with tumor cells genetically modified to express a cytokine, and treating the tumor with radiotherapy.
Type:
Grant
Filed:
February 2, 1996
Date of Patent:
April 18, 2000
Assignee:
The Regents of the University of California
Abstract: A DNA comprises an oligonucleotide antisense to mRNA encoding an adenosine A.sub.1 or A.sub.3 receptor. The oligo is provided as a composition, various formulations, a capsule, and cartridge and in the form of a kit. The oligonucleotide of the invention is effective for reducing bronchoconstriction and/or allergy, and may be administered to a subject to treat respiratory ailments such as asthma and other conditions associated with the expression of adenosine receptors.
Abstract: An adherent, stable, continuous human breast carcinoma cell line (GI-101A) has been produced from an infiltrating ductal breast carcinoma xenograft (GI-101) which has been grown and maintained in athymic mice for the past nine years. The GI-101A cells grow with an average doubling time of about 48 to about 72 hours. The cells display antigenic determinants consistent with those of the human breast tumor xenograft (GI-101) from which it was derived. The cell line, GI-101A, when injected subcutaneously into the subaxial area of athymic animals, such as athymic mice, produces tumors that spontaneously metastasize to distant organ sites, such as the lungs and lymph nodes. The cell line and the tumors that it produces may be used as model systems for study mechanisms responsible for metastatic behavior and for testing for new as well as screening for effective new anti-cancer drug therapies.
Type:
Grant
Filed:
October 27, 1997
Date of Patent:
March 14, 2000
Assignee:
Goodwin Institute for Cancer Research
Inventors:
Shula Raney, Dennis Emma, Josephine Hurst
Abstract: The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics.
Type:
Grant
Filed:
March 20, 1998
Date of Patent:
March 7, 2000
Assignees:
Myriad Genetics, Inc., Endo Recherche, Inc., HSC Research & Development Limited Parntership, Trustees of the Univ. of Pennsylvania
Inventors:
Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M. Rommens, Barbara L. Weber
Abstract: A method of reducing bronchoconstriction in a subject in need of such treatment is disclosed. The method comprises administering to the subject an antisense oligonucleotide molecule directed against the A.sub.1 or A.sub.3 adenosine receptor in an amount effective to reduce bronchoconstriction. The method is useful for treating patients afflicted with asthma. Pharmaceutical formulations are also disclosed.
Abstract: Disclosed is a method of directing a cellular response in a mammal by expressing in a cell of the mammal a chimeric receptor which causes the cells to specifically recognize and destroy an infective agent, a cell infected with an infective agent, a tumor or cancerous cell, or an autoimmune-generated cell. The chimeric receptor includes an extracellular portion which is capable of specifically recognizing and binding the target cell or target infective agent, and (b) an intracellular portion of a protein-tyrosine kinase which is capable of signalling the therapeutic cell to destroy a receptor-bound target cell or a receptor-bound target infective agent. Also disclosed are calls which express the chimeric receptors and DNA encoding the chimeric receptors.
Type:
Grant
Filed:
February 24, 1995
Date of Patent:
December 21, 1999
Assignee:
The Massachussetts General Hospital
Inventors:
Brian Seed, Charles Romeo, Waldemar Kolanus
Abstract: An oligonucleotide which is antisense to a mRNA encoding a polypeptide involved in airway disease(s) contains up to three adenosines per every 21 nucleotide a method of treating airway disease in a subject in need of such treatment comprises topically administering to the subject an antisense oligonucleotide in an amount effective to treat the airway disease, where the antisense oligonucleotide is essentially free of adenosine. Pharmaceutical formulations are also disclosed.
Abstract: A murine model for human ovarian and prostate cancer is provided. The model comprises an immunodeficient mouse containing human primary ovarian or prostate carcinoma tissue implanted within the gonadal fat pad. Methods of using the murine model, for example, to grow tumors and to screen treatments for ovarian and/or prostate cancer are also provided.
Abstract: Methods for increasing the nephron mass of a mammalian recipient are disclosed. A metanephros from an allogenic or xenogeneic mammalian donor is implanted next to a recipient's omentum or under the renal capsule of the recipient's kidney. The metanephros becomes vascularized by the recipient's blood vessels, forming a chimeric kidney that produces urine and develops a ureter that facilitates externalization of the urine. A ureter to ureter anastomosis can be subsequently performed to provide fluid communication between the chimeric kidney ureter and a ureter of the recipient.
Abstract: Nucleic acids are compacted, substantially without aggregation, to facilitate their uptake by target cells of an organism to which the compacted material is administered. The nucleic acids may achieve a clinical effect as a result of gene expression, hybridization to endogenous nucleic acids whose expression is undesired, or site-specific integration so that a target gene is replaced, modified or deleted. The targeting may be enhanced by means of a target cell-binding moiety. The nucleic acid is preferably compacted to a condensed state.
Abstract: Disclosed are transgenic mice carrying a human HLA-DQ sgene. The transgenic mice are deficient in mouse H-2 class II molecules. Such mice provide animal model systems to identify peptides useful for preventing or treating rheumatoid arthritis. Also disclosed are methods and materials for treating rheumatoid arthritis, including administration of peptides having specific binding affinity for HLA-DQ molecules expressed in a rheumatoid arthritis patient.
Type:
Grant
Filed:
August 31, 1995
Date of Patent:
October 12, 1999
Assignee:
Mayo Foundation for Medical Education and Research
Inventors:
Harvinder S. Luthra, Chella S. David, Eric Zanelli
Abstract: Gene therapy by using specific expression vectors within the epidermis or epidermal cells. These vectors incorporate regulatory sequences of tissue and differentiation-specific genes.
Type:
Grant
Filed:
November 1, 1993
Date of Patent:
September 28, 1999
Assignee:
Baylor College of Medicine
Inventors:
Dennis R. Roop, Joseph A. Rothnagel, David A. Greenhalgh
Abstract: Disclosed is a method of localized immunosuppression which may be used for preventing graft rejection or for preventing tissue destruction due to autoimmune disease. Also disclosed is a protein suppressor factor that is secreted by cloned anergic T-cells, blocks interleukin 2 (IL-2) stimulated T-cell proliferation, has an apparent molecular weight of between 10 and 30 kilodaltons, can be inactivated by heating to 65.degree. C. for 15 minute, blocks interleukin 4 (IL-4) stimulated T-cell proliferation in vitro, is non-cytotoxic to T-cells, and does not inhibit the production of IL-2 by T-cells in vitro.